Biocartis
In Brief This Week: Cepheid, Biocartis, Sight Diagnostics, Fluidigm, Co-Diagnostics, and More
News items for in vitro diagnostics industry for the week of Jan. 10, 2022.
Numerous technologies in development to help with the diagnosis of sepsis have a singular objective ─ detect the condition as quickly as possible.
Immunexpress Receives FDA 510(k) Clearance for Sepsis Assay
The assay, which runs on the company's Idylla platform, distinguishes sepsis from noninfectious systemic inflammation.
Biocartis H1 Revenues up 31 Percent
The revenue growth was driven by sales of the company's Idylla molecular diagnostics system and related test cartridges.
Biocartis Receives €1.4M Grant to Develop New Technology for Molecular Surveillance
The grant will support development of next-generation technology for the firm's Idylla platform that would allow for the offline customization of cartridges.
Feb 25, 2021
Biocartis Reports 15 Percent Rise in 2020 Revenues
Nov 12, 2020
Biocartis Q3 Cartridge Volume Grows 61 Percent
Nov 10, 2020
Biocartis Gets CE Mark for SARS-CoV-2 RT-PCR Test
Sep 3, 2020